Modified Double-Stranded Oligonucleotide Patent - Alnylam Pharmaceuticals
Summary
USPTO granted patent US12600965B2 to Alnylam Pharmaceuticals, Inc. covering modified double-stranded RNA (dsRNA) agents capable of inhibiting target gene expression. The patent, filed November 5, 2019, includes 38 claims and covers pharmaceutical compositions comprising these dsRNA molecules for therapeutic applications. Inventors include Donald Foster, Mark K. Schlegel, and Christopher Brown.
What changed
USPTO granted patent US12600965B2 to Alnylam Pharmaceuticals covering modified double-stranded RNA (dsRNA) agents for inhibiting target gene expression. The patent includes 38 claims relating to dsRNA molecules and pharmaceutical compositions for therapeutic use in treating disease conditions. CPC classifications include C12N 15/113 and related subclasses.
For pharmaceutical companies and investors, this patent grant provides Alnylam with enforceable intellectual property rights covering dsRNA-based therapeutics. The 20-year patent term runs from the November 5, 2019 filing date. Biotech firms developing similar RNA interference technologies should review this patent to assess potential licensing needs or design-around strategies.
What to do next
- Monitor patent portfolio for licensing opportunities
- Review product pipeline for dsRNA-related development
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Modified double stranded oligonucleotide
Grant US12600965B2 Kind: B2 Apr 14, 2026
Assignee
Alnylam Pharmaceuticals, Inc.
Inventors
Donald Foster, Mark K. Schlegel, Christopher Brown
Abstract
One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
CPC Classifications
C12N 15/113 C12N 2310/11 C12N 2310/315 C12N 2310/344
Filing Date
2019-11-05
Application No.
17291775
Claims
38
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.